FORT WORTH, TX / ACCESSWIRE / October 30, 2019 / Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or “the Company”) (OTCQB:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced an update today to its strategic plans.
Acute Care/Surgical Division Expansion
Sanara’s Acute Care/Surgical Division continues to expand its Regional Sales Manager (“RSM”) and 1099 network. By January 2020, the division expects to grow to over 20 RSM employees. The RSMs recruit, train, and support the 1099 independent sales team, which has tripled in size since the start of Q2 2019. Currently, the additional sales personnel are being trained and recently began selling the Company’s surgical products across nearly all surgical specialties in their respective territories. Through the use of its expanding sales force, Sanara believes there are significant opportunities for increased market penetration and geographic expansion.
The RSM’s and 1099 representatives work with hospitals and ambulatory surgical centers around the country to bring Sanara Activated Collagen® products to patients that could be positively impacted by their use. On average, when entering a new care center, the Acute Care/Surgical Division expects that it will take its sales team 6-9 months to gain facility approval and acceptance. To aid in this process, the division has numerous trials running to support the efficacy and value proposition at these new locations.
Over the next year, the Company has an initiative to offer the BIAKŌS™ Antimicrobial Skin and Wound line of products to both the acute care and surgical markets throughout the United States.
Wound Care Division Expansion
By the end of the first quarter 2020, Sanara’s Wound Care Division plans to materially increase the number of RSM’s covering the continental U.S. market. The RSMs work with skilled nursing facilities, home health care providers, wound centers, physician offices, and hospitals where the Company’s products are used to treat patients. These facilities and providers are currently supplied by several national DMEs and distributors. Sanara also has signed a distribution agreement with an e-commerce site to support patients ordering the Company’s products when they are not on a plan of care.
The Wound Care Division continues to pursue corporate wound care formulary adoptions and pull-through in the facilities where Sanara’s products are approved for use. Additionally, Sanara is currently in negotiations with a number of national distribution companies to carry its products. The Company expects this initiative to provide access to a significant number of skilled nursing facilities and home health agencies ensuring that more patients are able to benefit from Sanara’s highly efficacious products. Similar to the Acute Care/Surgical Division, when entering a new care center, the Wound Care Division expects that it will take its sales team 6-9 months to gain facility approval and acceptance. Currently, the division is running several trials in support of these efforts at these new locations.
As previously announced, through a license agreement with its licensing and development partner, Rochal Industries LLC (“Rochal”), Sanara plans to launch its BIAKŌS™ Antimicrobial Barrier Film and CuraShield™ No Sting Skin Protectant products in the second quarter of 2020. Sanara continues to work with Rochal on a number of impactful new medical device designs with plans to bring them to market in the coming years. In 2020, the Company expects to introduce a gel to complement its BIAKŌS™ Antimicrobial Skin and Wound Cleanser. Both products would be effective against planktonic microbes as well and immature and mature biofilms. When used together, the cleanser can be used initially to clean a wound and disrupt biofilms (removing 99% in 10 minutes). The gel can then be applied and will remain in the wound for up to 72 hours eliminating biofilms between normal dressing changes.
In addition to the BIAKŌS™ gel, Sanara is also working with Rochal to develop a debrider, a flowable scaffold that can be used to fill tunneling or undermining wounds, an oxygen transport device for use in hypoxic wounds, and a liquid bandage to treat skin tears and other similar wounds and skin conditions.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets and distributes wound and skincare products to physicians, hospitals, clinics, and all post-acute care settings. We are constantly seeking long-term strategic partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, HYCOL™ Hydrolyzed Collagen, and PULSAR II™ Advanced Wound Irrigation™ (AWI). In addition, Sanara is actively seeking to expand within its six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Callon Nichols, Director of Investor Relations
SOURCE: Sanara MedTech Inc.
View source version on accesswire.com: